ClinicalTrials.gg
RecruitingNCT07339345Updated Jan 14, 2026

Prospective Single-Arm Clinical Trial of GO Regimen for HLH.

A Phase 2/3 interventional study of Golidocitinib in Lymphohistiocytosis, Hemophagocytic, sponsored by Beijing Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Beijing Friendship Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Jun 2025, registered Jan 2026).
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
14 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital — 7 open to participants now, 7 under way, 3 of them phase 3. Lymphohistiocytosis, Hemophagocytic · Beijing Friendship Hospital.

Planned enrollment
10th of 17
28 · median 30
Started
2025
the only one that year
Phase 2/3
2 of 21
1 open now
Registered
21st of 21
by date

Among the 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 21st registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

7 of the 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 14 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital, or all of them as a file.
02

Study summary

This study aims to investigate the efficacy and safety of Golidocitinib(GO) monotherapy in the treatment of hemophagocytic lymphohistiocytosis.

03

Conditions studied

  • Lymphohistiocytosis, Hemophagocytic

Keywords

  • Hemophagocytic Lymphohistocytosis
  • Golidocitinib
04

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Researchers evaluate patients with newly diagnosed or /relapsed HLH disease.
  2. Definite diagnosis of HLH: molecular diagnosis consistent with pHLH, or at least 5 of the 8 criteria in the HLH-2004 diagnostic criteria.
  3. Patients who are currently unsuitable or unable to undergo .
  4. Researchers estimate that the expected survival period exceeds one month.
  5. Patients must be at least 14 years of age and no older than 70 years of age, with no gender restrictions.
  6. Before the study began, TB was ≤10 times the ; Cr was ≤1.5 times the normal value.
  7. Serum antigen or antibody negative。
  8. antibody negative, or HCV antibody positive but HCV RNA negative.
  9. . and HBcAb are both negative. If either of the above is positive, peripheral blood hepatitis B virus DNA titer testing is required, with a titer of less than 1×10³ copies/ml.
  10. Echocardiography showed ≥ 50%.
  11. Women of childbearing age must be confirmed as not pregnant by a pregnancy test and must be willing to use effective during the study period and for at least 12 months after the last dose; all male participants must use contraception during the study period and for at least 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Heart function above grade II(including II) ().
  2. Pregnancy or lactating Women and reproductive-age patients who refused to use appropriate measures during this trial.
  3. Individuals who are allergic to GO or have a severe allergic constitution.
  4. Active bleeding of the internal organs.
  5. uncontrollable infection.
  6. Severe mental illness.
  7. History of non-melanoma skin cancer.
  8. Unable to comply during the trial and/or follow-up phase. Participate in other clinical research at the same time.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    HLH patients

    Initial diagnosis or presence of refractory/relapsed HLH disease or confirmed diagnosis of HLH.

    Drug: Golidocitinib

Interventions

  • Administer the GO regimen to HLH patients who meet the inclusion criteria, specifically Golicitinib 150 mg once daily.

06

What researchers measure

Primary outcomes

  1. Evaluation of treatment response

    A complete response was defined as normalization of all of the quantifiable symptoms and laboratory markers of HLH, including levels of sCD25, ferritin, triglyceride, blood cell count, hemophagocytosis, and level of consciousness (if CNS HLH is present). A partial response was defined as at least a 25% improvement in 2 or more quantifiable symptoms and laboratory markers as follows: sCD25 response was\>1.5-fold decreased; ferritin and triglyceride decreased at least 25%; without blood transfusion: Neutrophils \<500/ml must increase by 100% and be \>500/ml; neutrophils 500-2000/ml must increase by 100% and return to normal.; and for patients with ALT \>400 U/L, response was defined as an ALT decrease of at least 50%. No response is defined as not meeting the criteria for partial response.

    Time frame: Weeks 2, 4, 6, and 8 after the start of treatment

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    An adverse event is defined as an adverse medical condition (including worsening of a pre-existing condition) that occurs in a subject or clinical trial subject after receiving medication, regardless of whether it is causally related to the investigational drug. Serious adverse events are defined as AEs that meet one or more of the following criteria during any study period: death; immediate threat to life; and hospitalization or prolongation of hospitalization.

    Time frame: 30 days after the last dose is administered.

Other outcomes

  1. Survival

    Patient's HLH-related symptoms and auxiliary examination results

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2026
First posted
Jan 14, 2026
StartActual
Jun 27, 2025
Primary completionEst.
Jun 27, 2026
CompletionEst.
Jun 27, 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07339345
Responsible party
Zhao Wang (Doctor, Beijing Friendship Hospital) — Principal investigator
First posted
Jan 14, 2026
Start date
Jun 27, 2025
Primary completion
Jun 27, 2026 (estimated)
Completion
Jun 27, 2027 (estimated)
Last update
Jan 14, 2026

Study contacts

jingshi Wang, M.M.
Contact
wangjingshi987@126.com
86-13520280731
zhao Wang
principal investigator · Beijing Friendship Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion